Document:

Exhibit

	
		
	Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.
	Exhibit 10.21 

AMENDMENT TO
CONTRACT MANUFACTURING AGREEMENT

THIS AMENDMENT (“Amendment”) is made and entered into this 20th day of February, 2013 (“Amendment Effective Date”) by and between Fresenius Kabi USA, LLC (successor in interest to APP Pharmaceuticals, LLC) (“Fresenius”) and The Medicines Company (“MDCO”). 

Background

WHEREAS, the parties hereto are parties to that certain Contract Manufacturing Agreement dated January 22, 2012 (the “Agreement”) pursuant to which Fresenius agreed to manufacture, and MDCO agreed to purchase, Angiomax® finished drug product on the terms set forth therein; and

WHEREAS, the Agreement provided certain limitations on MDCO’s agreement to reimburse Fresenius Kabi for  Development Costs and Expenses and Capital Expenditures to be incurred by Fresenius as provided therein; and

WHEREAS, the parties desire to amend the Agreement to reflect revised amounts of Development Costs and Expenses and Capital Expenditures expected to be incurred by Fresenius Kabi and to allocate responsibility for such revised amounts between the parties.

NOW THEREFORE, the parties hereby agree to amend the Agreement as follows:

1.    The Agreement is hereby amended by deleting the terms “APP Pharmaceuticals, LLC” and “APP” and replacing them with “Fresenius Kabi USA, LLC” and “Fresenius Kabi”, respectively, wherever such terms are used in the Agreement.

2.    Section 3.2, Development Costs and Expenses, is hereby amended by deleting such Section in its entirety and replacing it with the following: 

The Development Costs and Expenses to be incurred by Fresenius Kabi during the term of the Agreement are set forth on Schedule D attached to this Amendment.  The parties agree that the Development Costs and Expenses shall not exceed $[**] U.S. Dollars in the aggregate.  The parties agree that each of them shall be responsible for Development Costs and Expenses, up to a total of $[**] U.S. Dollars in the aggregate, in accordance with the allocation provided in the following Table 1.  Fresenius Kabi shall invoice MDCO for MDCO’s portion of such Development Costs and Expenses within [**] days of being spent or incurred by Fresenius Kabi and MDCO shall pay all such invoices within [**] days of the date thereof. 

Table 1.  Development Costs and Expenses

	
			
	Calendar Year
	Fresenius Kabi
	MDCO

	2012
	[**]
	[**]

	2013
	[**]
	[**]

	2014
	[**]
	[**]

	2015
	[**]
	[**]

	2016
	[**]
	[**]

	2017
	[**]
	[**]

	Total
	[**]
	[**]

	Development Costs and Expenses Total
	

$[**]

3.    Section 3.3, Capital Expenditure Reimbursement, is hereby amended by deleting such Section in its entirety and replacing it with the following:

The principal items and categories of Capital Expenditures to be incurred by Fresenius Kabi during the term of the Agreement are set forth on Schedule E to this Amendment.  The parties agree that the Capital Expenditures shall not exceed $[**] U.S. Dollars in the aggregate.  The parties agree that MDCO shall be responsible for Capital Expenditures, not to exceed $[**] U.S. Dollars in the aggregate, as provided in the following Table 2.  Fresenius Kabi shall invoice MDCO for MDCO’s portion of such Capital Expenditures within [**] days of being spent or incurred by Fresenius Kabi and MDCO shall pay all such invoices within [**] days of the date thereof. 

Table 2.  Capital Expenditures

	
			
	

Calendar Year
	Fresenius Kabi
	

MDCO

	2012
	[**]
	[**]

	2013
	[**]
	[**]

	2014
	[**]
	[**]

	2015
	[**]
	[**]

	2016
	[**]
	[**]

	2017
	[**]
	[**]

	Total
	[**]
	[**]

	Capital Expenditures Total
	

$[**]

4.    If either Party determines that Development Costs and Expenses and/or Capital Expenditures in addition to those provided in this Amendment may be required, the Parties shall discuss in good faith whether such potential additional requirements are necessary and, if so, the amount thereof for which each Party shall be responsible; provided, however, that unless otherwise agreed in writing, neither Fresenius nor MDCO shall have any obligation for Development Costs and Expenses and Capital Expenditures in excess of the amounts set forth in this Amendment.

5.    Unless otherwise amended by this Amendment, all other terms and conditions of the Agreement shall remain in full force and effect.  In the event of any conflict between the terms of this Amendment and the Agreement, this Amendment shall govern.

IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of the Amendment Effective Date.

FRESENIUS KABI USA, LLC            THE MEDICINES COMPANY

By: /s/ John R. Ducker                By: /s/ Glenn Sblendorio        
Name:    John R. Ducker            Name:     Glenn Sblendorio        
Title:    President & CEO            Title:     President and CFO        

	
				
	SCHEDULE D
DEVELOPMENT COSTS AND EXPENSES

	Transfer Expense
	Cost per Unit
	Unit
	Total

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	

[**]
	

Total
	

$[**]

	
				
	SCHEDULE E
CAPITAL EXPENDITURES

	CapEx
	Cost per Unit
	Unit
	Total

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	[**]
	[**]
	[**]
	[**]

	

	

Total
	

$[**]Exhibit

        

EXHIBIT 10.33

Date:  August 1st, 2005

FIRST AMENDMENT TO 
CHEMILOG DEVELOPMENT AND SUPPLY AGREEMENT
This FIRST AMENDMENT TO CHEMILOG DEVELOPMENT AND SUPPLY AGREEMENT, made as of the _1   day of August, 2005, between UCB-BIOPRODUCTS S.A., now UCB S.A (“UCB”) and THE MEDICINES COMPANY (“TMC”).
WHEREAS, UCB and TMC are parties to that certain CHEMILOG DEVELOPMENT AND SUPPLY AGREEMENT, dated December 20, 1999 (the “Supply Agreement”; capitalized terms used herein having the meanings provided in the Supply Agreement); and
WHEREAS, the Parties desire to amend the Supply Agreement on the terms set forth herein.
NOW, THEREFORE, in consideration of the premises and the covenants and agreements contained herein, the Parties agree as follows:
		
	1.
	ARTICLE 8 - FORECASTS AND ORDERS FOR THE PRODUCT is deleted in its entirety and the following is substituted therefor:

“ARTICLE 8 – FORECASTS AND ORDERS FOR THE PRODUCT
		
	8.1
	Forecasts

		
	8.1.1
	Except as set forth in 8.1.2 below, on each July 1 during the remainder of the term of this Agreement (each, a “Base Volume Forecast Date”), TMC shall submit to UCB a forecast (each, a “Forecast”) of the amount of Product to be purchased by TMC in the calendar year commencing eighteen (18) months after the Base Volume Forecast Date (the “Forecast Year”).  Fifty percent (50%) of the amount of Product specified in each Forecast shall be referred to as the “Base Volume.”  Each Forecast shall constitute a binding purchase order for the Base Volume specified therein, and UCB agrees to supply and TMC agrees to purchase such Base Volume.  UCB shall supply the Base Volume over the course of the Forecast Year on a delivery schedule to be agreed upon.  The remaining fifty percent (50%) of Product specified in each Forecast is non-binding and shall be referred to as the “Variable Volume.”

1

		
	8.1.2
	On July 1, 2005 only, TMC shall submit to UCB a forecast of the amount of Product to be purchased by TMC for the calendar year beginning January 1, 2007 (the “2007 Forecast”).  The 2007 Forecast shall be binding as to twenty-six percent (26%) of the applicable API price for the raw materials needed to manufacture the Base Volume required by the 2007 Forecast.  On January 1, 2006, TMC shall have the right to reduce the 2007 Forecast (the “Adjusted 2007 Forecast”) at which time TMC shall be bound to the Base Volume specified in the Adjusted 2007 Forecast.  If TMC reduces the 2007 Forecast, it shall remain obligated for twenty-six percent (26%) of the applicable API price for the raw materials purchased by UCB to manufacture the Base Volume required by the 2007 Forecast.  To the extent any raw materials remain after manufacture of the Product pursuant to the Adjusted 2007 Forecast, UCB shall credit such raw materials against Product ordered by TMC on future Base Volume Forecast Date.

		
	8.2
	Beginning on April 1, 2006 and continuing on each January 1, April 1, July 1 and October 1 thereafter during the remainder of this Agreement (each, a “Variable Forecast Date”), TMC may place a firm order to purchase up to 33% of the Variable Volume for a Forecast Year to be delivered in the fourth calendar quarter after the Variable Forecast Date.  The aggregate amount of Product ordered on the Variable Forecast Dates in any calendar year may not exceed the Variable Volume for the applicable Forecast Year.

		
	8.3
	All Product shall be manufactured by UCB at its Braine l’Alleud, Belgium facility using the approved Chemilog manufacturing process registered and subsequently updated with relevant regulatory authorities.  UCB agrees to reserve capacity at its Braine l’Alleud, Belgium facility so as to ensure it is able in any calendar year to manufacture at least the quantity of Product supplied to TMC in the preceding calendar year.  UCB shall make its best commercial efforts to manufacture any additional quantities that TMC might forecast in a given calendar year and shall inform TMC in writing of its inability to meet any Base Volume or Variable Volume specified in a Forecast within thirty (30) days of the receipt of such Forecast.

		
	2.
	ARTICLE 21- EXCLUSIVITY OF SUPPLY the following Section 21.3 is added

		
	21.3
	UCB agrees that it will not supply any Product to any third party during the term of this Agreement.

		
	3.
	Except as expressly amended herein, the Supply Agreement remains in full force and effect and the Parties hereby ratify and confirm all of the terms and conditions thereof.

2

IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the date first above-written.
	
		
	THE MEDICINES COMPANY
	UCB S.A.

	By:   /s/ John D. Richards    
Name:   John D. Richards 
Title:   Vice President Manufacturing OP
	By:   /s/ A. Jorden    
Name:   A. Jorden 
Title:   President UCB Bioproducts

	 
	By:   /s/ Cleo Ricci    
Name:   Cleo Ricci 
Title:   B.U. Director
P.O. Alan Scarso

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]